In the Nasdaq composite, financial, consumer services and health-care sectors have seen their weightings more than double.» Read More
The biotech sector is growing faster than anywhere in the market. Jason Kolbert, Maxim biotech analyst, says the market is loving the certainty in the sector.
Sarissa Capital will nominate two directors to Ariad Pharmaceuticals' board and seek the "imminent retirement" of Chief Executive Harvey Berger.
The drug that has saved millions from malaria is losing its efficacy in a much larger swath of territory than was previously known. The NYT reports.
Receptos CEO Faheem Hasnain told CNBC that "there's only one strategy to run a business."
Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss.
Robert Hugin, Celgene chairman & CEO, discusses his company's outlook, pipeline, and breakthrough treatments for cancer and other diseases.
Biotech start-ups are developing drugs to treat China's biggest emerging diseases - from diabetes and Hepatitis B to respiratory illnesses and cancer.
Sarissa Capital, which has a seat on Ariad Pharmaceuticals' board, is seeking to replace the company's CEO and may mount a proxy fight, a source said.
Unilife Chairman & CEO Alan Shortall, discusses partnerships with major pharma and biotech firms to deliver more advanced drugs in syringes and pumps.
M&A experts forecast there will be more major pharma deals in 2015 — but the U.K. won’t be a focus and the deals won’t be done for tax reasons.
The Ice Bucket Challenge raised $115 million for the ALS Association last summer. A look at how those donations were used.
Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.
CNBC's Meg Tirrell reports where the money raised in the ALS ice bucket challenge went.
Outbreaks of measles and whooping cough in California have rekindled debates over "anti-vaxxers"——here is a map of where they live.
Pfizer is buying Hospira, which calls itself the world's leading provider of injectable drugs and infusion technologies. So what the heck are they?
AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.
Yaron Werber, Citigroup, shares his basket approach to investing in biotech stocks Gilead, Celgene and others.
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
Gilead Sciences posted strong sales of its hepatitis C drugs Harvoni and Sovaldi, sending its net profit up more than four-fold for the quarter.
Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.
Get the best of CNBC in your inbox